We examined the incidence and the effect of alcohol abuse on pelvic control (PC), disease-free survival (DFS), and overall survival (OS) in locally advanced cervical cancer patients undergoing definitive radiation therapy (RT).
I n 2013, there were an estimated 12,360 patients who were diagnosed with cervical cancer and 4020 deaths due to the disease in the United States. 1 However, in developing countries, cervical cancer remains the number-one cause of cancer-related deaths among women, with nearly 500,000 women diagnosed annually worldwide. The use of concurrent chemoradiation therapy has been shown to increase the survival and is a global standard of care for locally advanced cervical cancer. [2] [3] [4] [5] [6] In a meta-analysis of chemoradiation trials, the addition of chemotherapy to radiation improved the 5-year survival from 50% to 58%. 7 Throughout the last decade, there have been continuous strides to decrease the death rate in patients with locally advanced cervical cancer, with the anticipated discovery and use of novel therapeutics in the field. For example, the role of adjuvant chemotherapy after standard chemoradiation has been shown to improve the overall survival (OS) in a recent phase 3 randomized trial in Mexico. 5 However, intensification of therapy is not without potential significant toxicity; patients on this trial who received adjuvant chemotherapy experienced a higher risk of grade 3 and 4 toxicity: 86.5% versus 46.3%, respectively (P = 0.001). 8 Because of the potential for adverse side effects from treatment intensification and the poor disease-free survival (DFS) of locally advanced cervical cancer, there have been increasing efforts to target lifestyle modification to improve outcomes. There is a paucity of data in investigating the role of alcohol consumption and cervical cancer outcomes. In addition, if the selected modifications are targeted appropriately, this intervention can impact clinical practice and cancer outcomes and also improve the quality of care in the survivorship period.
Heavy alcohol use causes about 88,000 deaths per year in the United States, which makes excessive alcohol the third leading cause of lifestyle-related mortality. 9, 10 There is an average of 30 years of potential life lost for each death due to alcohol. 9 Alcohol use has a major impact on the health system and disease prevention. There were an excess of 2.7 million physician-related office visits and 1.2 million emergency room visits in 2006 related to heavy alcohol usage, with an estimated cost of $223.5 billion. 11 Alcoholism has health ramifications that include an increased risk of developing a variety of cancers, with a potentially increased risk of cancer recurrence. 12 The objectives of our study are to evaluate the incidence of heavy alcohol consumption in our locally advanced cervical cancer population and to determine the effects of this lifestyle behavior on DFS, pelvic recurrence, and OS.
METHODS

Patient Characteristics
Between July 2007 and June 2013, 95 patients received radiation or chemoradiation with brachytherapy for definitive treatment of locally advanced cervical cancer. After obtaining permission from our institutional review board, a retrospective review was conducted to determine alcohol consumption using the center for disease control definition of heavy alcohol consumption being >1 drinks per day on average (CDC: http:// www.cdc.gov/alcohol/fact-sheets/alcohol-use.htm).
Patient characteristics recorded included age, smoking habits, illicit drug usage, ethnicity, the Charleston comorbidity index, and the Karnofsky Performance Status. Recorded tumor characteristics included the stage and the tumor histology. Cervical cancers were staged on the basis of the International Federation of Gynecology and Obstetrics (FIGO) staging system. The cervical histology was based on pathology reports and categorized as squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma. Treatment parameters examined included the total treatment time of radiation, the type of chemotherapy and the number of cycles, external-beam radiation therapy (EBRT) and the brachytherapy radiation dosage, and the use of an external-beam radiation parametria boost.
Treatment Procedure
The patients were treated with concurrent chemotherapy consisting of weekly cisplatin 40 mg/m 2 or 5-fluorouracil 1000 mg/m 2 . They received EBRT to the entire pelvis using a 4-field conformal technique. Radiation was delivered in 5 fractions per week for a total of 45 Gy in 25 fractions, with a parametrial or lymph node boost given depending on the extent of the disease, typically consisting of 3 to 5 additional fractions. Patients subsequently underwent an intracavitary highdose-rate brachytherapy using a tandem and ring applicator. During brachytherapy, a rectal retractor was placed and the vagina was packed with gauze to minimize applicator movement. Computed tomography (CT) scout images and axial CT images of 3-mm slice thickness were obtained once the applicator was in place.
Three-Dimensional Treatment Planning
For 3-dimensional treatment planning after brachytherapy, we used Varian Eclipse BrachyVision (v 8.1). The following reference points were identified: the International Commission on Radiation Units and Measurements (ICRU) rectal points and Manchester's A and B points. The ICRU rectal point was defined as the point on the lateral plain film 5 mm behind the packing at the level of the tandem ring. A manual optimization was carried out using the planning software with a traditional loading pattern of the tandem and ring. The dose was normalized to point A with the high-dose-rate prescription dose of 6 Gy for 5 fractions or 8 Gy for 3 fractions. From 2007 to the beginning of 2011, the brachytherapy prescriptions were normalized to ICRU point A. Since 2011, our current practice is to normalize to ICRU point A and then use CT-based image-guided techniques, and adjust the dwell times manually to account for volumetric dose constraints to the high-risk clinical target volume, rectum, sigmoid, and bladder.
Statistical Methods
The relationship between heavy alcohol use and pelvic control, DFS, and OS was analyzed using multivariable Cox proportional hazards (PH) regression models. A P-value < 0.05 was considered to be statistically significant. All analyses were performed with SAS v9.2 (SAS Institute Inc., Cary, NC). Pelvic control was defined as the time from diagnosis to the last follow-up when the patient was free from any recurrence of the cancer. DFS was defined as the time from diagnosis to the last follow-up when the patient had a local or distant metastasis. OS was defined as the time from diagnosis to either death or the last follow-up.
RESULTS
Patient Characteristics
The study population consisted of 95 patients with an average age of 54.8 years (range, 27 to 91 y). In total, 54% of the patients were nonsmokers, 21% smoked <20 pack years, and 25% smoked >20 pack years. The mean age of the study population was 54.8 years, with a range of 27 to 91 years, with 88% of the patients above 40 years old. Eighty-nine patients (89.5%) were scored as not being heavy drinkers and 10 patients (10.5%) as heavy drinkers. Patient and tumor characteristics are summarized in Table 1 .
Treatment Characteristics
Eighty-two percent of the patients were treated within 56 days for their external beam and brachytherapy. The majority of the patients were treated with brachytherapy treatment for an average of 27.3 days. For chemotherapy, 86 patients (90.5%) received cisplatin, 2 patients (2.1%) received 5-fluorouracil, and 7 patients (7.4%) did not receive chemotherapy. Of those receiving cisplatin chemotherapy, 79 patients underwent 6 cycles (90.8%), 7 patients underwent 5 cycles (8.0%), and 1 patient underwent 1 cycle (1.2%). Of the 2 patients receiving 5-fluorouracil chemotherapy, both received 2 cycles. All patients underwent EBRT with an average dose of 47.7 Gy (range, 32.4 to 50.8 Gy). Of those undergoing EBRT, 32 patients received an additional boost dose to areas such as the parametrium and pelvic and/or para-aortic lymph nodes. Fourteen patients (14.7%) were treated with adjuvant hysterectomy after completion of chemoradiation therapy. None of the heavy alcohol patients had an adjuvant hysterectomy, as shown in Table 1 .
Outcomes
With a median follow-up time of 21 months, 76% of the patients were disease free in the pelvis, 16% of the patients experienced local or distant recurrence, 12% of the patients died due to cervical cancer, and 15% of the patients had a noncervical cancer-related death. Univariable Cox PH regression was used to study the relationship/association between pelvic recurrence and each predictor of interest, and it indicated that heavy alcohol ( > 1 drinks per day on average) (P = 0.029; hazard ratio [HR], 3.10; 95% confidence interval [CI]: 1.13, 8.56) had a statistically significant effect on pelvic recurrence as shown in Table 2 . In addition, heavy alcohol had a statistically significant effect on DFS (P = 0.005; HR, 6.19; 95% CI: 1.73, 22.18). On multivariable analysis considering smoking, age, ethnicity, the Charlson Comorbidity Index, the Karnofsky Performance Status, illicit drug usage, excessive alcohol, the lymph node status, the FIGO staging, histology, the chemotherapy regimen, and the radiation treatment time and dose, regression analysis indicated that excessive alcohol ( > 1 drinks per day on average) (P = 0.005; HR, 10.57; 95% CI: 2.07, 53.93) had a statistically significant effect on DFS as shown in Figure 1 . Furthermore, univariable Cox PH regression analyses indicated that heavy alcohol ( > 1 drinks per day on average) (P = 0.001; HR, 6.68; 95% CI: 2.10, 21.26) had a statistically significant effect, respectively, on OS as seen in Table 2 . Multivariable Cox PH regression was used to study the relationship between OS and predictors on the basis of the stepwise method to select these predictors with the significance level of 0.15 for entry into and staying in the model of 0.15.
The multivariable Cox PH regression analysis indicated that excessive alcohol ( > 1 drinks per day on average) (P = 0.001; HR, 10.80; 95% CI: 2.57, 45.40) was a statistically significant detriment to OS, as shown in Figure 2 . In addition, as smoking has been shown to influence cervical cancer outcomes, we explored the effect of smoking on our study population. Comparing the patients with a history of smoking with heavy alcohol use (7 patients) to those without heavy alcohol use (37 patients), the DFS did not differ between the groups, HR (1.37; 95% CI: 0.38, 4.99; P = 0.6357). For comparison of DS between the 2 groups, HR (smoking with heavy alcohol use vs. smoking without heavy alcohol use), 3.41; 95% CI: 0.91, 12.79; P = 0.0688. On examining the group of heavy alcohol smokers (7 patients) and the group of heavy alcohol nonsmokers (3 patients), there was no difference with regard to the DFS, HR (heavy alcohol smoker vs. heavy alcohol nonsmoker), 0.913; 95% CI: 0.09, 8.89; P = 0.9375.
DISCUSSION
The International Agency for Research on Cancer of the World Health Organization has classified alcohol as a group 1 carcinogen, with high rates of alcohol consumption increasing the risk of developing cancer in multiple organs, including the upper gastrointestinal tract, the lung, the liver, the large bowel, and the breast. 12, 13 For most of the current century, medicine has stressed the potential addictive and detrimental health effects of alcohol. 12 However, alcohol, unlike other habit forming addictions such as smoking, has an interesting effect on the body. At low doses, it can exhibit a potentially helpful effect on the body, whereas at higher doses, it leads to cancer and addiction. 12 Alcohol consumption on all-cause mortality is illustrated by a Jshaped mortality curve, with the ascending portion of the curve reflecting an increased risk of alcohol-related diseases such as cirrhosis, cardiomyopathy, cancers, and pancreatitis. 12, 14, 15 The association between alcohol consumption and gynecologic malignancy is not well established. 14 Although retrospective in nature, with a small number of patients classified as heavy drinkers, our study is hypothesis generating. We showed that alcohol consumption was significantly associated with a decreased DFS and OS and an increased risk of pelvic recurrence in locally advanced cervical cancer. We also examined the factors of potential treatment delays, with equal percentages within the 2 groups examined, with 80% of the patients completing within 56 days. The mechanism for alcohol consumption and cervical cancer recurrence is still under investigation. There is, however, sparse literature on the association of alcohol consumption and the risk of developing cervical cancer. 15 Alcoholism was associated with an increased risk of development of cervical intraepithelial neoplasia 1 in a study in Korea (P = 0.0001). 16 In this study, the authors showed that alcohol consumption and a high HPV DNA viral load were associated with the risk of CIN1, but not CIN 2/3 or cervical cancer in HPV-positive women. 16 There is likely a multiplicative interaction between the HPV viral load and alcohol consumption in cervical carcinogenesis. 14, 16 In addition, previous studies have reported the association between alcohol intake and high-grade CIN or cervical cancer. [16] [17] [18] Overall, the studies report the aforementioned J-shaped association between alcohol consumption and cancer deaths. 12, 18 Therefore, there remains controversy on whether the alcohol level is associated with the development of or is a cofactor to cervical carcinogenesis. Our study shows that heavy alcohol consumption increased the risk of DFS and OS. By targeting alcoholism and lifestyle factors, we are focussing on survivorship and longevity. Changing a cervical cancer patient's alcohol consumption can lead to improved health.
Although data investigating the risk of heavy alcohol consumption and its association with cervical cancer are not well established, we know that chronic alcohol use is a strong risk factor for a variety of cancers, including those of the head and neck, the liver, the colorectum, and the breast. 12, 14 Potential factors including the primary metabolite of ethanol, acetaldehyde, and oxidative stress could lead to the development of carcinogenesis. 19 DNA methylation is a key factor in epigenetic transcriptional mutations, and a downstream effect could lead to alcohol-primed cancer. Futhermore, alcohol can interfere with local DNA methylation mediated by S-adenosylmethionine and its related pathways. 19 There are additional theories on the effect of ethanol to the genome involving one carbon metabolism to increase the risk of carcinogenesis. 19 Gynecologic cancer treatment impacts patients' reported quality of life and lifestyle behaviors. 20 The purpose of survivorship clinics is for cancer surveillance and general health monitoring to alter long-term cancer-related outcomes and health-related survival. 20 These follow-up periods allow for a unique opportunity to investigate current lifestyle behaviors that impact health outcomes. Studies have shown that overall, cancer survivors are less likely than noncancerous controls to be current drinkers, but are more likely to be former drinkers. 21 Given the time constraints of healthcare providers, ideally one would better identify those patients at highest risk for alcohol dependency. Younger patients in the survivorship period are less likely than older ones to be light, moderate, or heavy alcohol consumers as defined by 1 to 2, 3 to 4, >4 drinks per day (71% versus 47%, P = 0.001) in a recent study by Bifulco et al. 20 Therefore, there may be age differences in the patient population that can allow for a more in-depth screening for alcohol dependency or addiction. Midlife adults are less likely to change their alcohol habit after a cancer diagnosis. 20 Confounding the ability to study alcohol consumption in this patient population is the varying degrees of heavy alcohol consumption. In our study, we chose the CDC definition of heavy alcohol usage.
At the time of cancer detection, treatment, or follow-up visits, our study shows that clinicians need to make better assessment of patient alcohol use to impact their cancer and overall health. How should we best determine the risk of alcohol dependency in our cervical cancer patients? Studies have shown that clinicians make a poor assessment of alcohol use as opposed to using validated alcohol risk questionnaires. 22 Four clinical interview questions, the CAGE questions, have proved useful in helping one to make a diagnosis of alcoholism. 23 The questions focus on Cutting down, Annoyance by criticism, Guilty feeling, and Eye-openers. The acronym "CAGE" helps the physician to recall the questions. 23 The simple mnemonic CAGE makes the 4 questions easy for a busy clinician to remember. 23 The CAGE questionnaire was designed to be a screening tool and not a diagnostic measurement of the amount of drinking, the frequency, or the pattern. 24 There have been more contemporary risk assessment models such as the Michigan Alcohol Screening Test, which consists of 24 questions that inquire about the drinking behavior or adverse consequences of alcohol drinking, and the Alcohol Use Disorders Identification Test (AUDIT), which was designed to be sensitive to signs of hazardous and harmful drinking and alcohol dependence. 25 Targeted research has shown the brief 5 question AUDIT (AUDIT-5) to perform as well as the more time consuming AUDIT for patients with alcohol dependency or addiction. 26 To follow-up the CAGE questionnaire, soliciting patients to reduce the amount and the frequency of alcohol use usually leads to an estimated lower than the actual number of alcoholic drinks per day. Thus, patients who admit to only 2 or 3 drinks per day may be giving an underestimate to themselves and the clinicians. Therefore, an option for a busy clinician is to screen patients with the CAGE questionnaire, and then follow-up with an AUDIT-5 questionnaire, as shown in Figure 3 . The degree to which physicians tend to overlook alcoholism and other addictions is substantial, with a major effect on cancer recurrence, and major health consequences in the survivorship phase of treatment. 21, 27 A recent study showed that alcoholism is highly prevalent and frequently underdiagnosed in patients with advanced cancer. 27 Alcohol dependency and addiction responds to treatment when discovered. In addition, in our patient population, more of the heavy alcohol patients were also concurrent smokers. Patients can be treated with psychotherapy, medication, and self-help programs such as Alcoholics Anonymous, which can increase the quality of life and promote health. Clinical trials have continued to demonstrate the benefits of alcohol treatment in promoting abstinence or reduced heavy drinking for an increased quality of life. 24 The current study suffers from the limitations associated with a retrospective review with the accompanying problems of selection bias and the potential for incomplete data records. In addition, our data are from a single institution with a small number of patients classified as being heavy drinkers. However, to minimize confounding due to selection bias, we included consecutively treated patients. In addition, our follow-up period was 36 months, which captures most of the cervical cancer failures as the disease recurrence rates are the highest in the first 2 years after treatment. Furthermore, our alcohol categorization is based on our social history collection clinical form and did not include the alcohol screening or dependency-validated questionnaires such as CAGE, AUDIT, or AUDIT-5.
CONCLUSIONS
In this small series of patients with heavy alcohol use, the data support the association that heavy alcohol use increases the risk of cervical cancer recurrence and mortality. Additional research and physician attention are required to elicit accurate alcohol usage to target alcoholism in this patient population to promote increased survival.
